Table 1. Demographic and disease characteristics of 129 patients undergoing pelvic exenteration between June 2010 and May 2019.
| Characteristic | Values | ||
|---|---|---|---|
| Patient characteristic | |||
| Age (yr) | |||
| ≥70 | 27 (20.9) | ||
| <70 | 102 (79.1) | ||
| BMI (kg/m2) | 25 (14–54) | ||
| <25 | 60 (46.5) | ||
| 25–34.9 | 46 (35.6) | ||
| 35+ | 14 (10.9) | ||
| Unknown | 9 (7.0) | ||
| ASA score | |||
| 1–2 | 90 (69.8) | ||
| 3 | 8 (6.2) | ||
| Unknown | 31 (24.0) | ||
| Hemoglobin (g/dL) | |||
| ≤10 | 25 (19.3) | ||
| >10 | 86 (66.7) | ||
| Unknown | 18 (14.0) | ||
| Creatinine (mg/dL) | 0.8 (0.5–4.1) | ||
| ≤1.2 | 96 (74.4) | ||
| >1.2 | 15 (11.6) | ||
| Unknown | 18 (14) | ||
| Albumin (mg/dL) | 38 (20–48) | ||
| <30 | 15 (11.6) | ||
| ≥30 | 94 (72.9) | ||
| Unknown | 20 (15.5) | ||
| Comorbidities at presentation | |||
| None | 72 (55.8) | ||
| 1 | 42 (32.6) | ||
| 2+ | 13 (10.1) | ||
| Unknown | 2 (98.4) | ||
| Frequencies of comorbidities | |||
| CVD/hypertension requiring medications | 35 (27.1) | ||
| Diabetes mellitus | 12 (9.3) | ||
| Depression or anxiety | 8 (6.2) | ||
| COPD or recent pneumonia | 7 (5.4) | ||
| Autoimmune disease | 3 (2.3) | ||
| Renal failure (acute/chronic) | 3 (2.3) | ||
| TIA | 2 (1.6) | ||
| Disease characteristics | |||
| Primary site | |||
| Cervical cancer | 90 (69.8) | ||
| Endometrial cancer | 24 (18.6) | ||
| Vaginal/vulvar cancer | 15 (11.6) | ||
| Timing | |||
| Primary treatment | 30 (23.3) | ||
| Recurrence | 79 (61.2) | ||
| Persistence | 20 (15.5) | ||
| Previous EBRT | |||
| Yes | 106 (82.2) | ||
| No | 23 (17.8) | ||
| Previous chemotherapy | |||
| Yes | 93 (72.1) | ||
| No | 36 (27.9) | ||
Values are presented as number of patients (%) or median (range).
ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; EBRT, external beam radiotherapy; TIA, transient ischemic attack.